Hyrimoz (Adalimumab)

Adalimumab, the active ingredient in Hyrimoz, is a TNF inhibitor presented as a solution for injection for subcutaneous use. It treats several autoimmune inflammatory conditions in adults, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis.

GNH USA supplies Hyrimoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hyrimoz is a TNF‑alpha inhibitor used across a range of chronic inflammatory diseases.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriatic arthritis: alleviates skin and joint symptoms and improves function. - Ankylosing spondylitis: decreases spinal inflammation and improves mobility. - Crohn's disease: induces and maintains remission of intestinal inflammation. - Ulcerative colitis: helps achieve remission and maintain symptom control. - Plaque psoriasis: clears skin lesions and reduces scaling.

Adalimumab may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Upper respiratory infections: common cold‑like symptoms. - Headache: mild to moderate intensity. - Rash: skin irritation or mild dermatitis.

Serious or Rare Side Effects: - Serious infections: tuberculosis, fungal or bacterial infections. - Malignancies: increased risk of certain cancers such as lymphoma. - Demyelinating disorders: new or worsening neurologic symptoms. - Hepatitis B reactivation: flare of chronic hepatitis B infection.

Before initiating therapy, clinicians should assess patient history and monitor for adverse events.

- Screen for active infections: test for tuberculosis and hepatitis before starting. - Monitor for signs of infection: advise patients to report fever or cough promptly. - Assess cardiac status: avoid in patients with moderate to severe heart failure. - Evaluate vaccination status: avoid live vaccines during treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Adalimumab can interact with other immunomodulating agents and vaccines.

Major Interactions (Avoid): - Live vaccines: may cause severe infection; avoid concurrent use. - Concurrent TNF inhibitors: increased risk of immunosuppression.

Moderate Interactions (Monitor Closely): - Methotrexate: may enhance immunosuppressive effect. - Systemic corticosteroids: increased infection risk. - Azathioprine or cyclosporine: additive immunosuppression. - Antiviral therapy for hepatitis B: monitor for reactivation.